News & Events October

CTI Announces the FDA allows long term use of ISA247 in Isotechnika Phase 2b Clinical Program for the Prevention of Rejection following Kidney Transplantation

October 24, 2007

CTI Clinical Trial and Consulting Services (CTI) announced that Isotechnika has received permission from the U.S. Food and Drug Administration (FDA) for the long term use of ISA247 in patients currently participating in Isotechnika’s Phase 2b kidney transplant (PROMISE) trial. Isotechnika previously announced that they had also received a “No ...

Read More

Join Our Mailing List